VALNEVA Declaration of shares and voting rights January 31, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use ...
Shares of Valneva (VALN), a specialty vaccine company closed up over $1.00 per share or almost 19% to close the regular session at $6.67 per ...
Valneva (VALN) announced that the Medicines and Healthcare products Regulatory Agency or MHRA has granted marketing authorization in the United ...
UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq: Saint Herblain, France Thursday, February 6, 2025, 12:00 Hrs [IST] Valneva SE, a specialty vacci ...
H.C. Wainwright reaffirmed its Buy rating and $18.00 price target for Valneva (EPA:VLS) SE (NASDAQ:VALN) shares, following the recent approval of the company's Ixchiq vaccine in the United Kingdom ...
Hosted on MSN19h
Valneva’s chikungunya vaccine wins UK approvalValneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...
The company expects 2025 adjusted profit to be in the range of $8.15 to $8.35 per share, compared with the average of ...
Nyrstar NV - Update in respect of dissolution or continuation of the Company ...
US clinical-stage biotech Qlaris Bio has announced positive top-line results from two U.S. Phase II clinical trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback